Executive Summary

SJA executes deal structures with strategic partners seeking to outsource R&D via traditional and novel partnerships including:

  • Traditional in-licensing (“Buy” Side) and out-licensing (“Sell” Side) transactions
  • Direct External Innovation Models: Partnering around a specific company / project venture co-creation - large pharma participates with venture capital firms in early stages of launching
  • Built-to-Buy-Deals: Asset-centric drug discovery startups with pre-defined acquisition rights at development company / partner nomination

Out-Licensed South Korean Rights to Salarius / Iterion’s Oncology Small Molecules

  • Negotiated licensing terms – upfront payments, milestones, royalties
  • Established joint research committees monitoring progress and report findings to board members